The U.S. Food and Drug Administration (FDA) has now released detailed data regarding ninety-six (96) seafood entry line refusals in July, of which eight (8.3%) were for shrimp for reasons related to banned antibiotics.
The FDA has now reported refusing a total of fifty-one (51) entry lines of shrimp for reasons related to veterinary drug residues. Nearly half (24) of these entry lines have been of Indian shrimp.
The eight entry lines of shrimp refused for veterinary drug residues in July were attributed to shipments from four different exporters in India, Indonesia, and Vietnam. As noted below, three of the four exporters are Best Aquaculture Practices (BAP)-certified shrimp processors:
- Kader Exports Private Limited, Unit 5 (India), a company that currently operates under a four-star Best Aquaculture Practices (BAP) certification for its Unit 05 processing plant (P10460), with additional BAP certifications for multiple shrimp farms, and that was added to Import Alert 16-129 (“Detention Without Physical Examination of Seafood Products Due to Nitrofurans”) for its shipments of shrimp on April 1, 2024, had one entry line refused for shrimp contaminated with nitrofurans and veterinary drug residues by the Division of West Coast Imports on July 15, 2025
- Vasista Marine (India), a company that was added to Import Alert 16-129 (“Detention Without Physical Examination of Seafood Products Due to Nitrofurans”) on March 6, 2025 for the presence of nitrofurans in its shrimp, had five entry lines refused for shrimp contaminated with veterinary drug residues and nitrofurans by the Division of Southwest Imports on July 24, 2025;
- An Phu Factory – Soc Trang Seafood Joint Stock Company (Stapimex) (Vietnam), a company that currently operates the An Phu factory under a four-star BAP certification (P10326) with an additional BAP certification for another processing plant (P10162) and multiple BAP certifications for related shrimp farms, and that was added to Import Alert 16-124 (“Detention Without Physical Examination of Aquaculture Seafood Products Due to Unapproved Drugs”) on June 26, 2025 for the presence of amoxicillin in its shrimp, had one entry line refused for shrimp contaminated with nitrofurans and veterinary drug residues by the Division of West Coast Imports on July 7, 2025; and
- PT. Pabrik Lamongan BMI (Indonesia), a company that currently operates under a four-star BAP certification for its processing plant (P10680) and that was added to Import Alert 16-129 (“Detention Without Physical Examination of Seafood Products Due to Nitrofurans”) on June 30, 2025 for the presence of nitrofurans in its shrimp, had one entry line refused for shrimp contaminated with veterinary drug residues and nitrofurans by the Division of West Coast Imports on July 3, 2025.
Continuing its actions taken each month since February, the FDA refused another two entry lines from Indonesia’s Mega Marine Pride in July due to deficiencies with the labeling of sulfites that were present in its shrimp.
The FDA also reported that an entry line of shrimp from India’s Choice Trading Corporation was refused by the Division of Southwest Imports on July 15, 2025 as “filthy,” while three entry lines of breaded shrimp from Vietnam’s Tai Kim Anh Seafood Joint Stock Corporation were refused by the Division of Southeast Imports on July 24, 2025 as being contaminated with salmonella.